Abbvie earnings were $2.4B for the trailing 12 months ending Sep 30, 2025, with -53.8% growth year over year. The latest ABBV earnings report on Sep 30, 2025 announced Q3 2025 earnings of $186.0M, down 80.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABBV reported annual earnings of $4.3B, with -12% growth.
ABBV past earnings growth
How has ABBV's earnings growth performed historically?
On ABBV's earnings call on Invalid Date, Abbvie (NYSE: ABBV) reported Q3 2025 earnings per share (EPS) of $0.10, up 88.64% year over year. Total ABBV earnings for the quarter were $186.00 million. In the same quarter last year, Abbvie's earnings per share (EPS) was $0.88.
As of the last Abbvie earnings report, Abbvie is currently profitable. Abbvie's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $2.39 billion, a 53.38% decrease year over year.
What was ABBV's earnings growth in the past year?
As of Abbvie's earnings date in Invalid Date, Abbvie's earnings has grown -53.82% year over year. This is 407.07 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 353.25%. ABBV earnings in the past year totalled $2.39 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.